- Investing Ideas
- Swiss Pharmaceuticals & Biotech Healthy high growth potential
Swiss Pharmaceuticals & Biotech Healthy high growth potential
Results
4
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
4 companies
Kuros Biosciences
Market Cap: CHF 749.3m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 19.00
7D
3.2%
1Y
-30.7%
SKAN Group
Market Cap: CHF 1.3b
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.
SKAN
CHF 56.10
7D
2.7%
1Y
-21.0%
MindMaze Therapeutics Holding
Market Cap: CHF 30.5m
Operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally.
MMTX
CHF 0.20
7D
-9.1%
1Y
n/a
Cosmo
Market Cap: CHF 1.1b
A life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
COPN
CHF 68.10
7D
1.6%
1Y
14.8%